Loading...
OTCM
DVYSF
, Last price  
USD
Name

Devyser Diagnostics publ AB

Chart & Performance

D1W1MN
OTCM:DVYSF chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
252.01%
Rev. gr., 5y
27.53%
Revenues
217m
+28.12%
48,148,00064,303,00065,688,99993,481,000126,613,000169,300,000216,900,000
Net income
-62m
L+14.74%
519,0007,009,000-10,911,000-20,727,000-45,953,000-53,600,000-61,500,000
CFO
-47m
L-32.86%
6,020,00014,631,000627,000-16,482,000-40,501,000-69,700,000-46,800,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is headquartered in Hägersten, Sweden.
IPO date
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT